Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
about
Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaPotential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemiaMinimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesBlinatumomab: enlisting serial killer T-cells in the war against hematologic malignanciesPrognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemiaHow I treat acute lymphoblastic leukemia in older adolescents and young adultsCD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemiaFludarabine, idarubicin, and cytarabine regimen together with TKI followed by haploidentical hematopoietic stem cell transplantation, a success for relapsed Ph+ acute lymphoblastic leukemiaDetection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.Current status and future directions of clinical research and practice in adult acute lymphoblastic leukemia patients in KoreaTreatment of adolescent and young adults with acute lymphoblastic leukemiaMouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology.Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia.Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testingRole of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia.Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).New markers for minimal residual disease detection in acute lymphoblastic leukemia.Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas.Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemiaMinimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment.Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adultsDeep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.Measurements of treatment response in childhood acute leukemia.Cellular therapies in acute lymphoblastic leukemiaMonitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survivalMinimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemiaRNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantatiClinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.Adult acute lymphoblastic leukemia: concepts and strategies.Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Results from a Single Center, 1993-2011.Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.Treatment of acute lymphoblastic leukemia in adolescents and young adults.
P2860
Q26751269-B03CCF54-B605-4444-B19C-C27C8C5C90B9Q26764903-80018664-A2AE-48B7-8EC2-0DA48E4A1561Q26828511-EF93650A-C062-44DB-9DFA-E1AB98A6463BQ26865838-9993E966-4109-43E5-BD5E-7D2D9B2B2A2FQ27006773-A0E7DC2D-3637-416F-86B3-A207FCA4FAC2Q28087589-EC25FAB3-453A-46AD-8D72-031F4BC1ADBEQ29620607-9D13457D-EA0B-4136-8720-FE90D6217265Q30276948-7DCEE0DA-5243-4671-B272-E7C07251B445Q33614375-CB66099F-5223-4F03-96CF-9BA3CCEC93B2Q33875893-8EF70F71-024C-4950-9EC7-D84D67A8B8CFQ33920153-A8A84943-4CDF-499F-8B8E-CC1FAB2AB274Q34016431-E7348926-3BC6-4E0A-8CAC-C4B79D36D02CQ34333169-8EC1692C-E789-4707-A379-5E69C6B11346Q34425875-822EBC17-59F7-4EC8-867A-6C50BE853075Q34532041-F11D9974-90C1-4A1E-AD16-7E54628975C9Q34550540-DDAAE275-9787-4E65-BABF-E25FBB3DE681Q35067391-23FB2FBD-B2A6-4504-8F76-59B9904E06FCQ35224833-E44C3973-EC03-4FD9-8692-DCF931EC2A9FQ35669875-1773DF53-0B43-4F2C-9379-19366A284653Q35992927-D659C4CF-81C5-46E3-A853-59CD6F2A6A27Q36149287-B121E957-6AD3-49FB-A076-14F2D833C5C8Q36151241-7526F475-E0E9-40A6-A0A5-2A664ACD053FQ36182008-5E86B66E-0E03-4A18-B878-97B048AC9713Q36338763-F96F1471-5E4D-4EAC-9BFC-08D9DD1FA07AQ36461915-125CD4A0-50A9-4845-BABD-FED55622CB8AQ36509641-90F51389-1A3B-41B0-9CE6-15E3FE42F1B0Q36513773-89BB22E7-C990-461E-A2DF-FE9B7835D15CQ36552098-B6C41423-B1E3-4310-AF2D-0152925184BCQ36616666-2CE276FE-EB62-4D52-A185-ADFF38DC57F6Q36781786-F547FA19-9CC5-4BD9-A38D-4062139A53AAQ36781942-D972BFD2-FBF3-4668-B261-45F2BF88AF11Q37140482-D497701D-8440-4634-9327-4CFFD0766FD4Q37389544-A6E648CF-ACC9-4ECC-BA61-E49DF6D07688Q37555821-DEA7A820-795C-4952-A9C5-C8008CDF0104Q37619915-9493381A-EEB2-426D-AF23-398EDA1FAA7CQ37632798-D25814CC-E81F-435F-AE69-52BE59A1C004Q37681450-14C7BBA2-6AA0-4EAE-BAB9-54DE5E64A92AQ37682126-86A6A097-2964-4972-95A0-968ACE139EA6Q37685601-CEA5CE67-0CF0-4EDB-B596-681B42874647Q37899785-CA1AB657-10D5-42E4-AD15-FF3C7E5AB285
P2860
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Improved risk classification f ...... lymphoblastic leukemia (ALL).
@en
type
label
Improved risk classification f ...... lymphoblastic leukemia (ALL).
@en
prefLabel
Improved risk classification f ...... lymphoblastic leukemia (ALL).
@en
P2093
P50
P1433
P1476
Improved risk classification f ...... e lymphoblastic leukemia (ALL)
@en
P2093
Alessandro Rambaldi
Andrea Gallamini
Anna Maria Scattolin
Barbara Peruta
Claudio Romani
Elena Oldani
Elisabetta Terruzzi
Enrico M Pogliani
Erika Borlenghi
Eros Di Bona
P304
P356
10.1182/BLOOD-2008-11-185132
P407
P577
2009-01-13T00:00:00Z